

## **Publications in high impact journals in 2025**

1. Salivary glutamate and opiorphin as noninvasive markers of irreversible pulpitis in subjects with and without type2 diabetes. *Odontology*  
<https://doi.org/10.1007/s10266-025-01237-8>. **Impact 2.7**

2. Evaluation of salivary bone turnover markers and vitamin D as non-invasive, early predictive indicators of bone health in pre-, peri-, and post-menopausal women. *BMC Women's Health* (2026) 26:82. **Impact 3.5**  
<https://doi.org/10.1186/s12905-025-04238-5>.

## **Patents (Filed)**

1. Non-invasive salivary glutamate and opiorphin assay for symptomatic irreversible pulpitis pain. Patent Application no.02541134627

2. Non-invasive salivary Serotonin and IL1 beta assay for symptomatic irreversible pulpitis pain. Patent Application no.02541134628.